Treatments in Respiratory Medicine

, Volume 4, Supplement 1, pp 19–23 | Cite as

Clinical Significance of Pneumococcal Resistance and Factors Influencing Outcomes

  • William R. Bishai
Current Opinion


Despite increasing penicillin and macrolide resistance worldwide, the clinical relevance of this phenomenon is still unknown. Debate continues as to whether increasing resistance among pneumococci to β-lactam agents, macrolides, and fluoroquinolones has been accompanied by an increase in the rate of treatment failure. In vitro findings do not appear to be predictive of in vivo outcomes. Studies have failed to demonstrate significantly higher mortality for patients infected with penicillin-resistant rather than penicillin-susceptible pneumococcal strains. Treatment failures are associated solely with the highest levels of resistance. Antimicrobial resistance appears to affect other markers of morbidity, but only statistically nonsignificant trends toward increased mortality have been demonstrated. Whether macrolide resistance among invasive pneumococcal isolates is clinically relevant or a matter of limited influence remains to be determined.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000 Dec 28; 343(26): 1917–24PubMedCrossRefGoogle Scholar
  2. 2.
    Plouffe JF, Breiman RF, Facklam RR, on behalf of the Franklin County Pneumonia Study Group. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. JAMA 1996 Jan 17; 275(3): 194–8PubMedCrossRefGoogle Scholar
  3. 3.
    Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995 Aug 24; 333(8): 474–80PubMedCrossRefGoogle Scholar
  4. 4.
    Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J 1995 Oct; 14(10): 885–90PubMedCrossRefGoogle Scholar
  5. 5.
    Rahav G, Toledano Y, Engelhard D, et al. Invasive pneumococcal infections. A comparison between adults and children. Medicine (Baltimore) 1997 Jul; 76(4): 295–303Google Scholar
  6. 6.
    Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999 Jun; 159(6): 1835–42PubMedGoogle Scholar
  7. 7.
    Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000 Mar; 30(3): 520–8PubMedCrossRefGoogle Scholar
  8. 8.
    Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000 Feb; 90(2): 223–9PubMedCrossRefGoogle Scholar
  9. 9.
    Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003 Jul 15; 37(2): 230–7PubMedCrossRefGoogle Scholar
  10. 10.
    Falcó V, Almirante B, Jordano Q, et al. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains? J Antimicrob Chemother 2004 Aug; 54(2): 481–8PubMedCrossRefGoogle Scholar
  11. 11.
    Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000 May 22; 160(10): 1399–408PubMedCrossRefGoogle Scholar
  12. 12.
    Turett GS, Blum S, Fazal BA, et al. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999 Aug; 29(2): 321–7PubMedCrossRefGoogle Scholar
  13. 13.
    Brown SD, Farrell DJ. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001–2002. J Antimicrob Chemother 2004 Sep; 54 Suppl 1: i23–i29PubMedCrossRefGoogle Scholar
  14. 14.
    Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C, et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998–1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45(12): 3334–40PubMedCrossRefGoogle Scholar
  15. 15.
    Reinert RR, Al Lahham A, Lemperle M, et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002 Feb; 49(1): 61–8PubMedCrossRefGoogle Scholar
  16. 16.
    Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001 Oct 17; 286(15): 1857–62PubMedCrossRefGoogle Scholar
  17. 17.
    Hsueh PR, Teng LJ, Lee LN, et al. Extremely high incidence of macrolide and trimethoprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan. J Clin Microbiol 1999 May; 37(4): 897–901PubMedGoogle Scholar
  18. 18.
    Aspa J, Rajas O, Rodriguez de Castro F, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004 Mar 15; 38(6): 787–98PubMedCrossRefGoogle Scholar
  19. 19.
    Henriques B, Kalin M, Ortqvist A, et al. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. J Infect Dis 2000 Oct; 182(3): 833–9PubMedCrossRefGoogle Scholar
  20. 20.
    Rzeszutek M, Wierzbowski A, Hoban DJ, et al. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Int J Antimicrob Agents 2004 Aug; 24(2): 95–104PubMedCrossRefGoogle Scholar
  21. 21.
    Jackson MA, Burry VF, Olson LC, et al. Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr Infect Dis J 1996 Dec; 15(11): 1049–51PubMedCrossRefGoogle Scholar
  22. 22.
    Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000; 118(6): 1839–40PubMedCrossRefGoogle Scholar
  23. 23.
    Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002 Mar 21; 346(8): 630–1PubMedCrossRefGoogle Scholar
  24. 24.
    Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002 Sep 1; 35(5): 556–64PubMedCrossRefGoogle Scholar
  25. 25.
    Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964 May; 60: 759–76PubMedGoogle Scholar
  26. 26.
    Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003 Sep 15; 37(6): 752–60PubMedCrossRefGoogle Scholar
  27. 27.
    Rieux V, Carbon C, Azoulay-Dupuis E. Complex relationship between acquisition of beta-lactam resistance and loss of virulence in Streptococcus pneumoniae. J Infect Dis 2001 Jul 1; 184(1): 66–72PubMedCrossRefGoogle Scholar
  28. 28.
    Ambrose PG. Antimicrobial susceptibility breakpoints: PK-PD and susceptibility breakpoints. Treat Respir Med 2005; 4 Suppl. 1: 5–11Google Scholar
  29. 29.
    Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004 Feb; 125 (2 Suppl): 52S–60SPubMedCrossRefGoogle Scholar
  30. 30.
    Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003 Oct 1; 290(13): 1749–56PubMedCrossRefGoogle Scholar
  31. 31.
    Sakito O, Kadota J, Kohno S, et al. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63(1): 42–8PubMedCrossRefGoogle Scholar
  32. 32.
    Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994 Jun; 49(6): 531–2PubMedCrossRefGoogle Scholar
  33. 33.
    MacLeod CM, Hamid QA, Cameron L, et al. Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv Ther 2001 Mar; 18(2): 75–82PubMedCrossRefGoogle Scholar
  34. 34.
    Garey KW, Rubinstein I, Gotfried MH, et al. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 2000; 118(6): 1826–7PubMedCrossRefGoogle Scholar
  35. 35.
    Rechtweg JS, Moinuddin R, Houser SM, et al. Quality of life in treatment of acute rhinosinusitis with clarithromycin and amoxicillin/clavulanate. Laryngoscope 2004 May; 114(5): 806–10PubMedCrossRefGoogle Scholar
  36. 36.
    File Jr TM, Tan JS. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides. Drugs 2003; 63(2): 181–205PubMedCrossRefGoogle Scholar
  37. 37.
    File Jr TM, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004 May; 125(5): 1888–901PubMedCrossRefGoogle Scholar
  38. 38.
    Ball P, Make B. Acute exacerbations of chronic bronchitis: an international comparison. Chest 1998 Mar; 113 (3 Suppl): 199S–204SPubMedCrossRefGoogle Scholar
  39. 39.
    Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000 May; 117 (5 Suppl 2): 380S–5SPubMedCrossRefGoogle Scholar
  40. 40.
    Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000–01. J Infect 2004 Jan; 48(1): 56–65PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • William R. Bishai
    • 1
  1. 1.Johns Hopkins University Center for Tuberculosis ResearchBaltimoreUSA

Personalised recommendations